Management of calcium and bone abnormalities in hemodialysis patients

Seminars in Nephrology

Volumn 24, Issue 5, 2004, Pages 446-448

  Morii, Hirotoshi ^a,b,e   Inoue, Tayuki ^b   Nishijima, Takaaki ^b   Tomokuni, Takashi ^b   Ishikawa, Takatoshi ^b   Moriya, Kenji ^b   Kawai, Nobuaki ^b   Araki, Hiroyuki ^b   Horio, Misa ^b   Shigeoka, Tsutomu ^b   Tani, Koji ^b   Yamaguchi, Tadashi ^c   Kubodera, Noboru ^d  

^a Osaka Prefecture University   (Japan)

^b Osaka   (Japan)

^c KIRIN BREWERY CO LTD   (Japan)

^d CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^e OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

hyperparathyroidism Vitamin D analogs; hyperphosphatemia; hypocalcemia; phosphate binder

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; CALCITRIOL; CALCIUM ION; CALCIUM SENSING RECEPTOR; FALECALCITRIOL; PARATHYROID HORMONE; SEVELAMER; VITAMIN D; VITAMIN D DERIVATIVE;

BONE DISEASE; CALCIUM METABOLISM; CLINICAL TRIAL; CONFERENCE PAPER; HEMODIALYSIS PATIENT; HORMONE RELEASE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOPARATHYROIDISM; KIDNEY FAILURE; OSTEITIS FIBROSA; OSTEOMALACIA; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; SOFT TISSUE CALCIFICATION;

BONE DISEASES; CALCIUM METABOLISM DISORDERS; HUMANS; RENAL DIALYSIS; VITAMIN D;

EID: 5444240339     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2004.06.016     Document Type: Conference Paper

References (12)

1. Japanese Society for Dialysis Therapy: An overview of regular dialysis treatment in Japan. a. as of December 31, 2002. b. as of December 1998. c. as of December 31, 2000
2. L.D. Quarles, B. Lobaugh, G. Murphy Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia J Clin Endocrinol Metab 75 1992 145 150
3. Y. Kimura, M. Nakayama, S. Kuriyama Pharmacokinetics of active vitamin D3, 1,hydroxyvitamin D3 and 1,25-dihydroxy vitamin D3 in patients on chronic hemodialysis Clin Nephrol 35 1991 72 77
4. S. Koshikawa, T. Akizawa, K. Kurokawa Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism Nephron 90 2002 413 423
5. T. Akizawa, M. Suzuki, T. Akiba Long-term effect of 1, 25-dihydroxy-22-oxavitamin D3 on secondary hyperparathyroidism in hemodialysis patients. One-year administration study Nephrol Dial Transplant 17 suppl 10 2002 28 36
6. S. Komuro, H. Kanamaru, I. Nakatsuka Disposition and metabolism of ST-630 (2) Metabolism after single administration of 3H-ST-630 in rats [Japanese with English abstract] Pharmacodynamics 11 1996 518 529
7. H. Morii, T. Inoue, M. Fukunaga Efficacy and safety of long-term oral falecalcitriol treatment in patients with renal osteodystrophy J Bone Miner Metab 16 1998 44 54
8. Abstract of 48th Congress of Japanese Society for Dialysis Therapy J Jap Soc Dial Ther 36 suppl 1 2003 431 434
9. E. Slatopolsky, J. Finch, M. Denda Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro J Clin Invest 97 1996 2534 2540
10. P. Fourman, P. Royer, M.J. Levell Calcium metabolism and the bone 1968 Blackwell Scientific Publications Oxford
11. P. Raggi Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in hemodialysis patients Clin Nephrol 54 2000 325 333
12. G.M. Chertow, S.K. Burke, P. Raggi Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients Kidney Int 62 2002 245 252